Martingale Asset Management’s Crinetics Pharmaceuticals CRNX Stock Holding History

Martingale Asset Management’s Portfolio CRNX Stock Details CRNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-6,701	Closed	-$225K	–	798
2025 Q1	$225K	Sell	6,701 -15,783	-70%	-$589K	0.01%	727
2024 Q4	$1.15M	Buy	22,484 +410	+2%	+$22.9K	0.03%	444
2024 Q3	$1.13M	Buy	+22,074	New	+$1.14M	0.03%	433
2023 Q4	–	Sell	-44,377	Closed	-$1.32M	–	801
2023 Q3	$1.32M	Sell	44,377 -3,803	-8%	-$78.4K	0.03%	363
2023 Q2	$868K	Hold	48,180	–	–	0.02%	482
2023 Q1	$774K	Buy	48,180 +2,500	+5%	+$46.3K	0.01%	513
2022 Q4	$836K	Buy	+45,680	New	+$805K	0.02%	507

Other funds holding CRNX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Martingale Asset Management's CRNX Position: Q2 2025 in Review

Martingale Asset Management sold out of Crinetics Pharmaceuticals (CRNX) in Q2 2025, closing a stake of 6,701 shares — an estimated $225K sold.

Martingale Asset Management first reported a position in CRNX in Q4 2022 and held it in 7 quarters. The position peaked at $1.32M in Q3 2023. 222 funds tracked by Wall St. Rank hold CRNX as of Q2 2025.

Martingale Asset Management reported no remaining Crinetics Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
Martingale Asset Management sold 6,701 Crinetics Pharmaceuticals shares in Q2 2025, an estimated $225K.
Martingale Asset Management first reported a position in Crinetics Pharmaceuticals in Q4 2022 and held it in 7 quarters.
Martingale Asset Management's Crinetics Pharmaceuticals position peaked at $1.32M in Q3 2023.
222 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q2 2025.

Based on Martingale Asset Management's 13F filing for Q2 2025, filed 11 Aug 2025.